Improve productivity and maximize resource use with tailored, holistic solutions
Are inefficiencies and resource constraints holding back your full production potential? At Avantor, we understand the challenges that downstream processing poses — and we’re here to help.
Partnering with us means more than just gaining access to best-in-class products and services. It means leveraging our technical expertise and consultative approach to help:
- Improve productivity and yield
- Maximize resource use and facility capacity
- Mitigate risks, ensuring the integrity and reliability of your processes
Explore our customized strategies that save you time, money, and resources while enhancing your ability to bring breakthrough therapies to market faster.
Are purification strategies for structurally diverse mAbs moving you forward, or holding you back? This article presents study data on new technologies that better remove impurities, reduce aggregation and improve stability, including a readily biodegradable viral inactivation solution, enhanced chromatography ligand and formulation excipients.
Biopharma companies often lack the capacity and infrastructure to handle large buffer volumes needed for mAb production. Avantor offers four key strategies to improve operational efficiencies and reduce facility footprint, such as pre-weighed, GMP-compliant raw materials or ready-to-use hydrated solutions. Learn more about these customizable solutions.
Despite selecting the right, compendial excipients for a balanced formulation, you may encounter obstacles that delay market deadlines. Learn how to streamline the formulation and fill-finish process with the right raw material selection, secure and efficient fluid pathway design, comprehensive regulatory support, and supply chain transparency.
Can biopharma manufacturers avoid extra costs, potential problems and wasted production time by designing a fully compliant (cGMP) manufacturing process early on? This article explores where planning ahead, using compendial raw materials of the highest quality and purity, can yield substantial benefits to both productivity and patient safety.
Scaling up monoclonal antibody (mAb) production can be challenging, but it doesn't have to slow you down. Explore how our large-volume handling solutions, GMP-grade chemicals and customized solutions for process development, optimization, and validation help you scale up quickly and meet regulatory standards with confidence.
